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a b s t r a c t
Human papillomavirus 16 (HPV16) is causative in human cancer. The E2 protein regulates transcription
from and replication of the viral genome; the role of E2 in regulating the host genome has been less well
studied. We have expressed HPV16 E2 (E2) stably in U2OS cells; these cells tolerate E2 expression well
and gene expression analysis identiﬁed 74 genes showing differential expression speciﬁc to E2. Analysis
of published gene expression data sets during cervical cancer progression identiﬁed 20 of the genes as
being altered in a similar direction as the E2 speciﬁc genes. In addition, E2 altered the splicing of many
genes implicated in cancer and cell motility. The E2 expressing cells showed no alteration in cell growth
but were altered in cell motility, consistent with the E2 induced altered splicing predicted to affect this
cellular function. The results present a model system for investigating E2 regulation of the host genome.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human papillomavirus 16 is a causative agent in around 50% of
all cervical carcinomas and 90% of HPV positive head and neck
cancers (zur Hausen, 2009). The genome of HPV16 is circular double
stranded DNA of approximately 8 kbp. The E2 protein of all
papillomaviruses binds as a homo-dimer to 12 bp palindromic
sequences in the long control region of the viral DNA via a carboxyl
terminal homo-dimerization and DNA binding domain (Desaintes
and Demeret, 1996). The amino terminal domain of E2 can regulate
transcription from adjacent promoters and in the case of HPV16 can
either increase or decrease transcription depending upon the level
of E2 protein and the cell type used for study (Bouvard et al., 1994).
In addition E2 binds to 3 target sites surrounding the viral origin of
DNA replication and via a protein–protein interaction recruits the
viral helicase E1 (Mohr et al., 1990; Sakai et al., 1996; Yasugi et al.,
1997). E1 then forms a di-hexamer that interacts with cellular DNA
polymerases and initiates viral genome replication (Masterson et al.,
1998). One further role for E2 in the viral life cycle is to act as the
mitotic receptor for the viral genome; E2 interacts with the host
genome via its amino terminus therefore tethering the viral genome
to that of the host during mitosis ensuring that the viral genomes
segregate to both daughter cell nuclei following cell division. Brd4 is
the mitotic receptor for some but not all E2 proteins (McPhillips
et al., 2006; You et al., 2004), TopBP1 is a potential cellular
candidate mediating HPV16 association with mitotic chromatin
(Donaldson et al., 2007).
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The large majority of studies on E2 have focused on regulation of
the viral genome. This report focuses on the regulation of the host
genome by HPV16 E2. Over expression of E2 can be toxic to many
cell types, particularly those transformed by papillomaviruses
(Desaintes et al., 1997; Goodwin et al., 1998; Parish et al., 2006).
One of the mechanisms of toxicity in these cells is mediated by E2
binding and repressing the promoter controlling the E6 and E7
oncogenes that target and functionally inactivate the tumor sup-
pressors p53 and pRb respectively. Repression of the viral onco-
genes reactivates the tumor suppressor pathways resulting in cell
growth inhibition and cell death (Hwang et al., 1996; Wu
et al., 2000). In some of these studies micro-array experiments
have been carried out to investigate the cellular genes that are
regulated by the over expression of E2 (Johung et al., 2007;
Morrison et al., 2011; Naeger et al., 1999; Ramirez-Salazar et al.,
2011; Thierry et al., 2004). By deﬁnition all of these studies have
been carried out transiently as the cells are destined for growth
inhibition or cell death, and the E2 protein is delivered by viruses or
plasmid over expression that will potentially add additional toxicity
to the cell. E2 is also toxic to non-HPV transformed cell lines and the
precise reasons for the toxicity are not certain although interaction
with p53 may play a role (Parish et al., 2006). A recent study
investigated the regulation of cellular genes by HPV16 E2 in C33a
cells, but again this was carried out using a viral delivery system
with transient expression levels of the E2 protein although clear
gene changes were observed independently of the presence of other
HPV proteins (Ramirez-Salazar et al., 2011). Jang et al. (2009)
investigated the interaction of E2 with chromatin and demonstrated
that in C33a cells E2 co-localizes with Brd4 on host chromatin
around actively transcribed genes, although there was no signiﬁcant
difference in the RNA levels of the genes E2 associates with; it was
proposed that this localization of E2 in active chromatin facilitates
the viral life cycle. Another recent study investigated the E2 binding
sites present in the host genome and demonstrated that HPV11 E2
can interact with some of these sites, but again when binding
adjacent to active genes then the regulation of these genes was,
overall, not changed (Vosa et al., 2012). This supports the work of
Jang et al. (2009) and the hypothesis that E2 may bind near active
genes to ensure the virus is in an open chromatin conﬁguration
allowing viral transcription and replication. Therefore, all of this
work to date has not fully investigated the regulation of host genes
by any E2 protein with physiologically tolerated levels of E2. This is
important since it is possible that E2 assists in programming the cell
to accommodate infection and the viral life cycle by directly
targeting the host genome. To investigate this we used U2OS cells
as a model system.
U2OS cells were derived from an osteosarcoma and have many
positives for investigating the regulation of the host genome by E2.
First, these cells are p53 positive and retain a p53 response
following DNA damage (Allan and Fried, 1999); E2 binds to p53
and it is possible that it could regulate the p53 response (Massimi
et al., 1999). Although HPV16 E6 binds to and degrades p53 other
DNA virus families use multiple mechanisms to silence the p53
response and it is possible HPV does the same (Soria et al., 2010).
Second, U2OS cells tolerate physiological levels of HPV16 E2;
stable clones expressing E2 can be produced (Taylor et al., 2003).
We would like to stress that we are not claiming the E2 levels
present in the U2OS cells are totally reﬂective of those in HPV
lesions; these levels will be widely varied from lesion to lesion. But
the levels of E2 do not kill or growth arrest the cells allowing
investigation of E2 genome regulation in the absence of stress
and/or apoptosis pathways. Third, U2OS cells can retain HPV16
genomes as stable episomes providing a model system for screen-
ing the E2 target genes for disruption of episomal viral genome
maintenance (Grant et al., 2013; Reinson et al., 2013). Fourth, U2OS
cells are extremely tractable for future studies in determining how
E2 regulates host genes. ENCODE data has already been generated
on histone modiﬁcation patterns in U2OS cells and therefore
future studies investigating the E2 interaction with the host
chromatin and modiﬁcation of histone modiﬁcations using ChIP-
seq are technically achievable in this cell line (Grant et al., 2013).
Here we report that, in stable U2OS clones expressing HPV16 E2,
the cellular genome is altered at the level of gene expression and
exon splicing. These changes affect genes associated with cervical
cancer progression, as well as cell motility. U2OS represents a model
system for studying the effect of E2 on the host genome.
Results
Generation of stable U2OS cells expressing HPV16 E2
In order to establish U2OS cells expressing HPV16 E2 (which from
now on will be designated “E2” as all results presented are for HPV16
E2) a similar protocol to that previously published was carried out
(Taylor et al., 2003) (the older cell lines expressing E2 were established
over 10 years ago so fresh lines were prepared). Stable colonies
following transfection were isolated and expanded and screened for
E2 expression. Fig. 1a shows expression of E2 in two of these lines that
were chosen for further studies. From day to day the expression of E2
did not affect the growth of the U2OS cells as demonstrated using a
cell growth curve with the two clones (Fig. 1b).
Identifying differentially expressed host genes induced by E2
To investigate the regulation of the host genome by E2, RNA was
prepared and used for Affymetrix exon array studies. The protocol
Fig. 1. Initial characterization of HPV16 E2 expressing cells. U2OS clones expressing
E2 were generated and expression of E2 conﬁrmed using western blotting (a).
Clearly in lanes 1 and 3 there is E2 protein detectable; actin is used as a loading
control. To determine whether the expression of E2 had an effect on cell
proliferation cell growth curves were carried out (b). The two E2 expressing clones
behave very similarly to the two vector control clones demonstrating that E2 does
not alter the growth of cells. Error bars are included in this ﬁgure but as it is a log
scale they are too small to appear; the standard errors were relatively small. The
highest standard error varied 5% from the average but was ordinarily a lot lower.
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for preparing the RNA, processing, screening and analyzing the data
is given in “Materials and methods”; the experiment was carried
out in triplicate with freshly prepared RNA each time. Following this
experiment and the data analysis 74 genes were found to be
differentially regulated 2 fold or greater when E2 was compared
with the vector control (p-valuer0.05); 33 up-regulated and 41
down-regulated. These genes are listed in Table 1. Ten of the altered
genes were chosen to validate the array results in two independent
clones of E2 and the results are shown in Table S1. In E2 clone F
(which was used for the exon array experiments), 7 out of 10 gene
changes were validated while in E2 clone A, 10 out of 10 tested
validated. Overall this demonstrates that the results generated from
the exon array screen were predictive of actual gene changes.
Analysis of the 74 genes differentially expressed using DAVID (GO
Biological Process and KEGG Pathways) revealed no signiﬁcant groups
of gene changes likely due in part to the relatively small number of
genes involved. The 74 genes were also subjected to analysis using
Ingenuity Pathway Analysis software (www.ingenuity.com) which
identiﬁed 5 networks, shown in Figure S1. Table 2 lists the associated
functions with the networks; the presence of cancer, reproductive
system disease, gene expression, DNA replication and repair would be
predicted for a transcription and replication factor from an oncogenic
human papillomavirus. Table S2 lists all of the genes in these
networks and has an assigned signiﬁcance score from IPA.
Over-represented DNA sequences within promoters of E2-regulated
genes
We analyzed the promoters of genes altered in expression by E2
for DNA sequences with statistically signiﬁcant over-representation.
Analysis for 7mer sequences identiﬁed numerous sequences, one of
which (GGGATTA) matched the binding sites for the OBOX1 and
PITX3 transcription factor binding sites (p-value¼3108,
FDR¼0.00026). This association suggests a possible interaction
between E2 and these transcription factors that could result in
altered expression of these genes. None of the other sites identiﬁed
were potential transcription factor binding sites.
E2 induction of exon splice variation
E2 regulates splicing of HPV gene transcripts via interaction with
cell RNA splicing apparatus therefore the regulation of host RNA
transcript splicing by E2 was investigated (Johansson et al., 2012).
Our analysis of the exon array data showed 522 genes with
differentially spliced exons induced by E2, in which the fold
expression of E2 over control for one or more exons deviated
signiﬁcantly from the mean fold expression for all exons within
each transcript. A list of these genes is shown in Table S3. Most
genes had only one or a few exons differentially expressed com-
pared to the bulk of exons for each transcript. These genes did not
exhibit differential expression for the gene as a whole. Fig. 2 shows
two examples, the MARK2 gene and the KIF1a gene. MARK2 is a
protein kinase involved in microtubule regulation (Nishimura et al.,
2012). KIF1a is a kinesin motor involved in vesicle transport in
hippocampal neurons (Lo et al., 2011) that has also been implicated
in head and neck cancers (Demokan et al., 2010). The exon
expression analysis of the MARK2 gene showed one exon induced
in the presence of E2 in comparison to the 22 other exons being
expressed. For the KIF1a gene there are several of the early exons
that are elevated in their expression.
We analyzed the biologically associated properties of the E2-
induced alternatively spliced genes using DAVID and IPA to deter-
mine if these genes were random or were part of speciﬁc pathways
and biological processes. Table 3 summarizes results of the DAVID
analysis demonstrating that E2 regulates splicing of genes involved
Table 1
Genes regulated in U2OS cells by HPV16 E2. The list of genes was generated as
described in the “Materials and methods” and these genes represent those whose
overall transcriptional level has been increased or decreased by the levels
indicated. The results validated in the parental E2 clone and also an additional
E2 clone; the detail of the validation is presented in Table S1.
Up-regulated by E2 Fold-change Down-regulated by E2 Fold-change
HIST1H2BM 71.9508 GTSF1 302.705
HIST1H3H 70.7304 NFE4 24.794
MAGEC1 40.1869 TMPRSS15 11.624
SLN 14.5889 SLC14A1 5.94492
HOXB2 10.631 C1orf85 4.48436
TNFAIP6 4.86318 CD33 4.1363
ENG 4.85397 CLIC2 3.9316
GNG11 4.11702 FBXL13 3.60857
FAR2 3.70124 PTGFR 3.59376
ZNF788 3.3983 CSTA 3.49077
APBA2 2.99782 NLRP5 3.33859
SERPINA3 2.74046 DNAJC18 3.31614
C10orf72 2.5905 BMPER 3.27652
GFPT2 2.53867 HBE1 3.07671
SH3PXD2B 2.50361 RNF144B 3.04874
FAP 2.47498 GDF15 2.98979
LRRCC1 2.36516 LOC79015 2.97446
ARHGDIB 2.35827 HSD17B8 2.75366
SNTB1 2.25035 HIST1H3E 2.69962
EML1 2.23335 MLH3 2.64666
ARHGAP11A 2.23306 NLRP4 2.60899
CCDC99 2.16172 TRIML2 2.55713
FGD4 2.1616 CD68 2.47599
ZNF271 2.15217 ACYP1 2.43839
MTMR10 2.11787 PSG9 2.41357
CALHM2 2.11199 HLA-DPA1 2.38118
HNMT 2.09265 GNGT2 2.37174
GOLGA8B 2.08224 FST 2.35479
AQR 2.05191 GCNT2 2.3148
NFIA 2.02545 GRAMD3 2.29601
ZNF770 2.02363 PGAP2 2.20441
ZADH2 2.01373 RPL23 2.20367










Associated functions with IPA networks from E2 regulated genes. The 74 genes listed in Table 1 were subjected to IPA and 5 networks of genes were identiﬁed. The networks
are shown in Figure S1 and the genes associated with the networks listed in Table S2. The above table lists the predicted functions associated with the IPA generated
networks.
Network Associated network functions
1 Protein synthesis; protein degradation; hereditary disorders
2 Tissue morphology; cancer; reproductive system disease
3 Gene expression; cancer; renal and urological disease
4 Hematological system development and function; organismal development; cell morphology
5 Cellular assembly and organization; DNA replication, recombination, repair; gene expression
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adhesion/motility processes, and cytoskeletal re-organization. The
genes associated with these functions are presented in Table S4. In
addition, the genes with E2-induced alternatively spliced transcripts
showed a statistically signiﬁcant association with cancer genes from
the Network of Cancer Genes (http://bio.ieo.eu/ncg/). The cancer
genes are listed in Table S5.
Regulation of cell motility by E2
The exon analysis demonstrates that E2 alters splicing in genes
implicated in cell movement, and there were also genes implicated
in cell movement and motility altered in the fold gene expression
change analysis (Table 1). SH3PXD2B regulates EGF dependent cell
migration (Bogel et al., 2012) and lamellipodia formation (Lanyi
et al., 2011) and cell spreading. FGD4 promotes migration of
nasopharyngeal carcinoma cells infected with EBV (Liu et al.,
2012) while FAP is a homodimeric integral membrane gelatinase
involved in promoting invasion (Kelly et al., 2012). ARHGDIB is a
RhoGDP dissociation inhibitor that can regulate metastasis, poten-
tially by down regulating adhesion (Griner and Theodorescu,
2012). All of these genes are up-regulated in the gene set in
Table 1 and potentially may modulate migration of the E2
expressing cells.
To investigate whether this altered gene expression or RNA
splicing in the E2 expressing cells resulted in altered cell motility,
wound healing assays were carried out. The E2 expressing cells
were delayed in closing the gap between cells compared with
vector control cells and Fig. 3 displays the results from a repre-
sentative experiment. This experiment was carried out indepen-
dently three times with essentially the same results; the E2 cells
were always delayed in closing of the wound. As the E2 and Vec
expressing U2OS cells have the same growth rate (Fig. 1b) it was
hypothesized that the delay in wound closing by the E2 expressing
cells was due to altered cell movement. To further investigate this
movies were made of the E2 and Vec expressing cells over a 48 h
time period, the results of this are shown in Figure S2. It is clear
from the movies that the E2 cells move differently when compared
with the Vec cells; this result was duplicated with two indepen-
dent clones. Overall the results demonstrate that the E2 expressing
cells are altered in their ability to migrate.
A signiﬁcant sub-set of E2 regulated genes are altered in cervical
lesions
To determine whether any of the E2 regulated genes are altered in
cervical lesions, existing micro-array data was investigated. Three sets
of data generated from independent studies (Ng et al., 2007; Scotto et
al., 2008; Zhai et al., 2007) were used and the outcome of this analysis
is shown in Table 4. Table S7 contains the same set of genes with the
fold differences and p values listed. Of the 74 genes in Table 1, 20 were
regulated in the same direction in at least one of the data sets. This
represents a signiﬁcant percentage of the genes that are regulated by
E2 and raises the possibility that E2 can program host genomes during
infection. In many cervical cancers E2 expression is lost following
integration of the viral genome into that of the host (zur Hausen,
2009) but it is possible that E2 lays down an epigenetic marker on
genes that retains their regulation even in the absence of E2 protein.
Discussion
There have been few studies investigating the direct role of E2
in regulating host gene expression outside of the HPV cell line
Fig. 2. An example of genes alternatively spliced in the presence of HPV16 E2. Plots of relative expression of exon probesets for (A) MARK2 and (B) KIF1A. The ratios of E2 to
vector control for normalized expression values for each array exon probe are shown on the Y-axis for the MARK2 and KIF1A genes. The X-axis is labeled with the exon series
probes from the exon array as deﬁned by Affymetrix in the direction of transcription. For some array exon probes, multiple probes cover the same exon. Standard error bars
based on triplicate analysis are shown. We note that while the data shown is displayed as ratios, the statistical analysis to identify genes with differentially spliced RNAs was
based on Log2-transformed ratios.
Table 3
DAVID analysis of genes differentially spliced in the presence of E2. The source of
the analysis is given in the left hand column and the affected process in the right. A
list of genes associated with each process is listed in Table S4.
Source Process or pathway
KEGG pathway Focal adhesion
GO biological process Protein amino acid phosphorylation
GO biological process Phosphate metabolic process
GO biological process Phosphorus metabolic process
GO biological process Phosphorylation
KEGG pathway Regulation of actin cytoskeleton
KEGG pathway Viral myocarditis
GO biological process Actin cytoskeleton reorganization
KEGG pathway Insulin signaling pathway
KEGG pathway Ubiquitin mediated proteolysis
KEGG pathway Phosphatidylinositol signaling system
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systems where over expression results in repression of E6 and E7
expression and reactivation of the p53 and pRb tumor suppressor
pathways (Desaintes et al., 1997; Goodwin et al., 1998; Hwang
et al., 1996; Johung et al., 2007; Morrison et al., 2011; Naeger et al.,
1999; Parish et al., 2006; Thierry et al., 2004; Wu et al., 2000).
Such reactivation results in cell cycle arrest and apoptosis and
expression of E2 in these cells results in activation of genes and
pathways involved in these processes. To our knowledge this is the
ﬁrst report detailing analysis of host gene regulation by physiolo-
gically tolerated levels of E2 proteins; therefore the target genes
identiﬁed are not related to E2 induced apoptosis or growth arrest.
This is also the ﬁrst report, to our knowledge, demonstrating that
E2 can regulate the splicing of several hundred cellular transcripts
of host genes. Several of the genes regulated by E2 are involved in
cellular movement, and the differentially spliced gene population
also had a signiﬁcant representation of genes involved in cell
movement and motility. The E2 expressing cells grew similarly to
the vector control cells (Fig. 1b) but had diminished cellular
movement in wound healing assays (Fig. 3). We also investigated
the expression of the E2 regulated genes during cervical cancer
progression using micro-array data from previous reports with
clinical samples and demonstrated that 20 of the 74 E2 regulated
genes were regulated in a similar manner in at least one of three
clinical data sets. Overall the results demonstrate that E2 can
regulate the host genome at multiple levels by controlling cellular
gene expression as well as splicing of cellular transcripts.
The mechanism that E2 uses to regulate transcription from the
host genome is unclear. There are several thousand E2 binding sites
present in the human genome, many of them adjacent to actively
transcribed genes, but none of these genes are regulated in the
presence of E2 even although the E2 protein associates with the
predicted target sequences (Vosa et al., 2012). This suggests that E2
regulates the host genome not by binding to E2 DNA binding sites
adjacent to the regulated gene promoters but rather via interaction
with cellular proteins associated with the regulated promoters.
Analysis of these promoters revealed statistically over expressed
sequences putatively bound by cellular transcription factors, OBOX1
and PITX3. Both of these proteins are homeobox containing
Fig. 3. HPV16 E2 expressing cells are delayed in their ability to “wound” heal. This is a representative panel of images from a wound healing experiment that was carried out
three times with essentially the same result. For both of the Vec clones the wound is substantially healed after 16 h and almost fully closed at 24 h. For both of the E2 clones
signiﬁcant gaps remain at 16 h and also at 24 h. The results demonstrate that the E2 expressing cells are delayed in their ability to close the wound. This is a result of
alterations in cell movement as the E2 and Vec clones grow at a similar rate (Fig. 1b).
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transcriptional regulators, Obox1 is ordinarily expressed in germ
cells (Rajkovic et al., 2002) while PITX3 regulates neuronal devel-
opment (Smidt et al., 2004). Homeo-box genes are de-regulated in
cancer and E2 could regulate gene expression via these factors by
binding to promoters through OBOX1/PITX3 and altering transcrip-
tional control of these genes. We hypothesize that E2 can regulate
the host genome via interaction with transcriptional co-factors that
are targeted directly to host promoters by cellular DNA binding
transcription factors. E2 is known to bind a host of cellular proteins
and therefore there are many candidates for mediating E2 regula-
tion of host transcription. For example, E2 can bind the histone
modifying proteins CBP (Lee et al., 2000) and p300 (Kruppel et al.,
2008; Quinlan et al., 2013) and these can regulate E2 function. E2
can also bind the chromatin associated factor Brd4; this protein is
essential for E2 regulation of transcription from HPV and synthetic
promoters that have E2 DNA binding sites so may also be involved
in regulation of host genes via interaction with Brd4 located at host
promoters (Schweiger et al., 2006). E2 also binds the cellular
chromatin binder TopBP1 that is essential for HPV DNA replication
control (Donaldson et al., 2012); TopBP1 can also regulate transcrip-
tion of host genes therefore is an additional candidate for mediating
E2 transcriptional regulation of the host (Liu et al., 2011; McPhillips
et al., 2004). There are many other candidates that could be
involved in the control of host gene expression by E2 and further
work is required to identify which factors are involved.
The mechanism that E2 uses to regulate host gene splicing is
also unclear. Previous reports have suggested that E2 may regulate
the expression of splicing factors in U2OS cells (McPhillips et al.,
2004); we do not observe this at the transcriptional level (Table 1).
It seems more likely that E2 can interact directly with splicing
factors in order to alter splicing of cellular genes and is consistent
with known interactions between E2 and splicing factors (Bodaghi
et al., 2009). It is entirely possible that the interaction between E2
and splicing factors regulates their stability. In addition, regulation
of viral gene splicing by E2 has been observed (Johansson et al.,
2012). Future studies will focus on understanding how E2 is
altering the expression of exons within genes, this is the ﬁrst
report demonstrating such a regulation of the host genome by E2.
Regulation of the host genome by E2 could clearly facilitate the
viral life cycle in several ways. Table 4 demonstrates that E2 can
regulate genes altered in the progression of cervical lesions. This is
the ﬁrst report demonstrating alteration of host gene splicing by
E2 therefore there are no comparisons that can be made. It is of
note that the alteration in the expression and splicing of genes
involved in cell movement and motility were detected and that the
E2 expressing cells had a reduced cellular motility when compared
with wild type cells. A recent paper demonstrated that E2 can up
regulate cell motility but this was done in the background of HPV
positive cells making it difﬁcult to compare with the results
presented here (Morrison et al., 2011). In cervical cancers the
HPV genome is integrated in the majority of cases, resulting in loss
of the E2 gene (Mair et al., 2014; zur Hausen, 2009). It has been
proposed that this loss of E2 results in elevation of E6 and E7
expression as their promoter is no longer repressed; such eleva-
tion could contribute to genomic instability and the transformed
phenotype. The control of cell motility by E2 could also be lost in
these transformed cells when E2 expression is lost further con-
tributing to progression to carcinogenesis. This loss of E2 control
could be mediated by the absence of regulation of gene splicing, or
due to altered gene regulation. It is possible that a sub-set of the
changes in host gene expression by E2 can be inherited into
daughter cells via epigenetic regulation following E2 loss, but also
that there is another sub-set of E2 regulated genes whose regula-
tion is lost upon the loss of E2 expression.
Future studies will focus on enhancing our understanding of
how E2 regulates the host genome. This regulation is likely
essential to manipulate the host genome to allow progression of
the viral infection. We hypothesize that chromatin modiﬁcations
at the E2 regulated promoters are responsible for alterations in
gene expression. Understanding the precise modiﬁcations
involved would present opportunities to reverse the control of
the cellular genome by E2. Our understanding of the chromatin
Table 4
Regulation of E2 target genes in micro-array data from clinical samples. Three previous studies looking at gene regulation by HPV infected cells (Ng et al., 2007; Scotto et al.,
2008; Zhai et al., 2007) were studies for alterations in genes regulated by E2 listed in Table 1. Column 2 details the fold changes listed in Table 1. Columns 3 and 4 list genes
altered from one study investigating gene changes from low grade cervical squamous intraepithelial lesions (column 3) and high grade cervical squamous intraepithelial
lesions (column 4), both compared with normal cervix (set 1). Columns 5 and 6 list genes altered from another study investigating gene changes from high grade cervical
squamous intraepithelial lesions (column 5) and cervical squamous cell carcinomas (column 6) versus normal cervix (set 2). Column 7 summarizes results from interrogating
a data set comparing gene expression from cervical squamous cell carcinomas versus normal cervix (set 3). Raw data are available at Gene expression omnibus (GEO) and the
















CSTA 3.5 Down Down Down
HLA-DPA1 2.4 Down
GCNT2 2.3 Down Down
RPL23 2.2 Down
AURKC 2.1 Down
ADRB2 2.1 Down Down Down
GOLGA8B 2.1 Up Up Up Up
ZNF271 2.2 Up Up
CCDC99 2.2 Up Up Up
ARHGAP11A 2.2 Up Up
ARHGFIB 2.4 Up
FAP 2.5 Up Up
SERPINA3 2.7 Up Up Up Up




HOXB2 10.6 Up Up Up
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modiﬁcations responsible for regulating gene expression increases
exponentially; great efforts are being directed at being able to
manipulate these modiﬁcations to alleviate and treat disease (Mair
et al., 2014). Such an approach could be used to reverse the
regulation of the host genome by E2 and assist with the disruption
of the HPV life cycle. It is also possible that the modiﬁcations by E2
could be inherited epigenetically into daughter cells so even when
E2 expression is lost, reversing the effect of E2 regulation of the
host genome may still affect the HPV transformed cell. We propose
the U2OS system as a tractable model to understand how E2
regulates the host genome at both a transcriptional level and at a
gene splicing level.
Materials and methods
Generation of stable U2OS clones
U2OS cells were grown in Dulbecco's modiﬁed eagle medium
(DMEM) with 10% Fetal Calf Serum and 1% (v/v) penicillin/
streptomycin mixture (Invitrogen) at 37 1C in a 5% CO2/95% air
atmosphere. Cells were passaged every 3–4 days. To make stable
cell lines expressing E2 4105 U2OS cells were plated onto
100 mm2 plates. The following day cells were transfected using
the calcium phosphate method, with 1 mg of E2 encoding plasmid
DNA containing a G418 resistance gene (Bouvard et al., 1994). 48 h
post-transfection, cells were treated with 0.5% trypsin EDTA
(Invitrogen), and re-plated at several dilutions (1:5, 1:20 and
1:50) and fed with DMEM media containing G418 (Geneticin) at
a concentration of 0.75 mg/ml. Cells were monitored and re-fed
every 3–4 days with fresh G418 media, for 14 days post the initial
G418 treatment. After this time isolated colonies of surviving cells
were seen. These colonies were transferred using cloning rings to
6 well plates, and cultures were maintained in G418 medium.
Candidate clones were then expanded into 75 cm2 ﬂasks. The
presence of E2 was tested using western blotting.
Western blotting
Cells were trypsinized and then washed twice with phosphate
buffered saline. Pellets were then re-suspended in 100 ml lysis
buffer (0.5% Nonidet P-40, 50 mM Tris, pH 7.8, 150 mM NaCl,
protease inhibitor cocktail (Roche)). The cells were then lysed on
ice for 30 min, and the lysates cleared (10 min at 20,800 rcf at
4 1C). The supernatant was then removed to a clean tube. Protein
levels were determined using a BCA Assay (Sigma).
30 μg of cell lysate for each sample was prepared and loaded
onto a 4–12% gradient gel (Invitrogen), electrophoresed at 200 V
for 1 h and transferred onto nitrocellulose membrane. Membranes
were incubated in blocking buffer (5% NFMP, 0.1% Tween-20, PBS )
at RT for 1 h then incubated with TVG261 mouse anti-HPV16 E2
antibody diluted 1:10 in blocking buffer. Membranes were washed
in PBS-0.1%Tween then incubated with secondary antibody (anti-
Mouse Ig, Horseradish Peroxidase linked) (GE Healthcare) diluted
1:50,000 in blocking buffer at RT for 90–120 min. Following
another wash with PBS-0.1%Tween the chemiluminescence was
developed using ECL-Plus (Amersham Biosciences) and the mem-
brane exposed to ﬁlm.
Growth curve
2105 cells were seeded in 100 mm2 plates in triplicate and
grown in complete DMEM medium; cells were trypsinized and
counted using a hemocytometer. This process was repeated three
times in 3 days intervals. Growth curves of two separate sets of
U20S vector and 16E2 wild type clones were plotted on a log scale
from the successive cell counts, 0, 3, 6 and 9 days.
RNA preparation
1106 stably transfected U20S cells were plated out on
100 mm plates. The following day cells were washed 2 with
PBS. 600 μl of buffer RLT from the Qiagen RNeasy kit was added to
each plate and incubated at room temperature for about 5 min;
cells were then scraped from the plate and buffer RLT/cell mix was
added to a Qiashredder column (Qiagen) and centrifuged follow-
ing the manufacturer's instructions to homogenize the sample.
The Qiagen RNeasy protocol was then followed to extract RNA
from the U2OS cells. DNA was removed using DNase treatment
(Qiagen) on column.
Exon array
Three independent polyAþ RNA preparations were made from
the same clone (U2OS E2 clone F) and converted to cDNA and
analyzed using Affymetrix Gene Chip Human Exon 1.0ST Array.
1.5 mg of RNA was required for the analysis. The quantity and
quality of the RNA were analyzed using the Agilent 2100 Bioana-
lyser System. cDNA preparation, the microarray assay, and primary
analysis were performed in Glasgow Polyomics at the University of
Glasgow using standard Affymetrix protocols. Brieﬂy, the sense
strand cDNA was generated from total RNA using the Ambion WT
Expression Kit (Applied Biosystems) followed by fragmentation
and terminal labelling using the Affymetrix GeneChip WT Term-
inal Labelling Kit. The samples were then hybridized to the arrays
using Hybridization Oven 640. The arrays were washed and
stained using Fluidic Station 400 and scanned on the Gene Array
Scanner 7G. The raw data in form of Affymetrix CEL ﬁles were
generated from scanned images with GCOS software (Affymetrix).
The raw data representing a selection of probes corresponding to
the core annotation level were then normalized using GC-content
by the Robust Multichip Average method followed by differential
expression analysis using ANOVA module within Genomics Suite
(Partek Inc.).
SYBR green qPCR
Sybr green real-time qPCR was used to validate the array gene
expression results (DyNAmo SYBR Green qPCR Kit with ROX) using
primers designed by Qiagen (Qiagen QuantiTech primer assay).
The house keeping gene GAPDH was used as an endogenous
control alongside the Vector, no E2 expressing U20S cell line to
normalize the results using the ΔΔct method. A list of genes
validated can be found in Table S1.
Identiﬁcation of E2-regulated genes with over-represented DNA
sequences within promoters
The promoter sequences within 1 kbp immediately upstream of
the transcription start site of genes identiﬁed as regulated by E2
were analyzed for representation of all 7mer sequences. The
hypergeometric distribution was used to assess p-values. Over-
represented sequences were identiﬁed based on p-value and false
discovery rate. Identiﬁcation of potential transcription factor
binding sites based on these sequences was performed using
TOMTOM (Gupta et al., 2007).
Identiﬁcation of genes with differential splicing in the presence of E2
The ratio of mean replicate expression data for the E2-
expressing cells to the mean replicate expression data for vector
control cells was calculated for each exon. The Log2 transformed
exon ratios were ﬁtted to a normal distribution and statistically
signiﬁcant outlier exons were identiﬁed based on p-values and
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false discovery rates. Genes with these exons represent proposed
alternatively spliced transcripts. Exons expressing values near
background in both E2-expressing cells and vector control cells
were excluded from the analysis.
Identiﬁcation of genes differentially expressed during cervical cancer
progression
Expression of E2-regulated genes was analyzed in the following
datasets of cervical SCC samples with published gene expression
proﬁles: 32 samples of lesional epithelium microdissected from
cervical high-grade squamous intraepithelial lesions (HSILs) and
low-grade SILs (LSILs) and 12 samples of normal ectocervical
squamous epithelium (set-1) (Ng et al., 2007); 21 cervical SCC,
7 HSIL plus 10 normal cervix (set-2) (Zhai et al., 2007); and 32
cervical SCC plus 21 normal cervix (set-3) (Scotto et al., 2008). All
microarray data were obtained from the GEO database, with the
accession numbers GSE27678, GSE7803 and GSE9750. We used
ANOVA, with a post-hoc analysis by the Student–Newman–Keuls'
test to determine genes differentially expressed during cervical
cancer progression (fold change41.5-fold and p valueo0.05).
Wound assays
To determine cell migration, “wound-healing” (scratch) assays
were used. Cell culture inserts (Ibidi, cat # 80209) were attached
to 6 well plates and seeded with 5104 cells in each side of the
cell insert divide. This was done in replicate for each Vector and
16E2 wildtype U2OS clone. Cells were grown for 24 h until each
side of the chamber was conﬂuent. The cell insert was removed
and images captured at time points 0, 16 and 24 h (Zeiss, Axiovert
200 M microscope and Axiocam). The width of the cell free gap
was approximately 500 μm (750 μm) at time 0 h; measurements
were performed using Axiovision software at multiple points of
the wound for each time point. These measurements were used to
calculate the average distance the cells moved over a 24 h period.
An average of three separate experiments was taken.
Wound assays – live cell imaging
8-well chamber slides were seeded with 5104 cells in each
well. This was done in replicate for each Vector and 16E2 wildtype
U2OS clone. Cells were grown for 24 h until conﬂuent. A scratch
was made in the center of each well, using a 20 μl pipette tip. Cells
were imaged over time, using a Zeiss AxioObserver Z1 microscope
equipped with an Axiocam MRm CCD camera, a motorized XY
stage that permits multi-point imaging and a Pecon stage incuba-
tion system to maintain cell viability. For these scratch assays, a
10 /0.3 EC Plan-Neoﬂuar Ph1 objective lens was used. Zeiss Zen
Blue software was used to program the system to record images
from each well at 5-min intervals for 48 h. The halogen lamp was
shuttered between time points and a green ﬁlter was placed in the
optical path to minimize the effects of photo-toxicity. By necessity
the results from these experiments are supplementary ﬁgures.
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